Harnessing the Power of Proteomics to Assess Drug Safety and Guide Clinical Trials.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 29506994.
- Also identified by DOI 10.1161/CIRCULATIONAHA.117.032876 and PMC identifier 5842814.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Assessing drug safety and efficacy is costly, and many promising candidates can present unwanted side effects. Can new developments in proteomic biomarkers help provide timely monitoring of efficacy and protect participant safety? In this issue, Williams <i>et al.</i> tackled this question with a retrospective study on whether patients treated with torcetrapib in the ILLUMINATE trial showed signs of increased cardiovascular risks early in the trial.
Medical subject headings
- Proteomics
- Quinolines